Who is sponsoring NCT02364531?

NCT02364531 is sponsored by Janssen Inc..

What drugs are being tested in NCT02364531?

Interventions in NCT02364531: Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry.

What condition does NCT02364531 study?

NCT02364531 studies Prostatic Neoplasms.

Is NCT02364531 still recruiting?

NCT02364531 is currently completed. Last updated 6 December 2019.

Last reviewed 2019-12-06 · How we verify

NCT02364531: COSMiC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting

Completed Last updated 6 December 2019

What this trial tests

trial testing Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry in Prostatic Neoplasms in 194 participants. Completed in 1 November 2018.

Timeline

30 September 2014

Primary endpoint
1 November 2018

1 November 2018

Quick facts

Lead sponsor	Janssen Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	194
Start date	30 September 2014
Primary completion	1 November 2018
Estimated completion	1 November 2018
Sites	41 locations across Canada

Drugs / interventions tested

Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry

Conditions studied

Prostatic Neoplasms — all drugs for Prostatic Neoplasms →

Sponsor

Janssen Inc. — full company profile →

Who can join

18 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to temporally evaluate the impact of abiraterone acetate (ZYTIGA) therapy on Patient Reported Outcomes (PROs) and on clinical outcomes in the chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) population. Safety data, levels of health care resource utilization associated with abiraterone acetate (ZYTIGA) therapy will also be prospectively collected and analyzed.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients.
Daisley BA, Chanyi RM, Abdur-Rashid K, Al KF, et al · · 2020 · cited 102× · PMID 32973149 · DOI 10.1038/s41467-020-18649-5
Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC.
Gotto G, Drachenberg DE, Chin J, Casey R, et al · · 2020 · cited 10× · PMID 32569568 · DOI 10.5489/cuaj.6388
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors.
Wefel JS, Ryan CJ, Van J, Jackson JC, et al · · 2022 · cited 9× · PMID 35522374 · DOI 10.1007/s40263-022-00913-5
2018 CUA Abstracts.
· 2018 · PMID 29877793
Podium Session 1: Prostate Cancer June 26, 2016 1050–1150
· 2016

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasms

Currently open trials in the same condition.

NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting

Other Janssen Inc. trials

Trials by the same sponsor.

NCT03729349 — Golimumab for Adherence in Rheumatoid Arthritis · completed
NCT03501173 — A Study of Participants With Advanced Prostate Cancer in Canada · completed
NCT02688075 — An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in · completed
NCT01483599 — A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis · Phase 2 · completed
NCT00741793 — Biologic Treatment Registry Across Canada · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02364531 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Inc.
Last refreshed: 6 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02364531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing